Graham Capital Management L.P. Acquires 113,417 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Graham Capital Management L.P. grew its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 435.1% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 139,482 shares of the company's stock after buying an additional 113,417 shares during the period. Graham Capital Management L.P.'s holdings in Bausch Health Companies were worth $1,124,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Tobam raised its position in shares of Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after buying an additional 1,422 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Bausch Health Companies by 7.9% during the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after buying an additional 1,896 shares during the last quarter. American Century Companies Inc. raised its position in Bausch Health Companies by 10.6% in the fourth quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock worth $220,000 after purchasing an additional 2,600 shares in the last quarter. Blair William & Co. IL raised its position in Bausch Health Companies by 3.2% in the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after purchasing an additional 2,622 shares in the last quarter. Finally, Sanders Morris Harris LLC raised its position in Bausch Health Companies by 16.0% in the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after purchasing an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BHC shares. StockNews.com lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Finally, Royal Bank of Canada increased their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $7.42.

Bausch Health Companies Stock Performance

Bausch Health Companies stock traded up $0.08 during trading hours on Friday, hitting $4.68. 1,151,316 shares of the stock were exchanged, compared to its average volume of 2,610,353. The stock has a market capitalization of $1.69 billion, a P/E ratio of -38.96, a P/E/G ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $9.85. The business's 50-day moving average is $5.55 and its two-hundred day moving average is $6.96.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. On average, equities analysts predict that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.